DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
3.505
-0.035 (-0.99%)
Apr 21, 2025, 4:00 PM EDT - Market closed

Company Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.

Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis.

The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.

DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc.
DiaMedica Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Dietrich Pauls

Contact Details

Address:
301 Carlson Parkway, Suite 210
Minneapolis, Minnesota 55305
United States
Phone 763 496 5454
Website diamedica.com

Stock Details

Ticker Symbol DMAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401040
CUSIP Number 25253X207
ISIN Number CA25253X2077
SIC Code 2834

Key Executives

Name Position
Dietrich John Pauls MBA President, Chief Executive Officer and Director
Scott Kellen CPA Chief Financial Officer and Corporate Secretary
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer
Dr. Ambarish Shah Ph.D. Chief Technology Officer
Dominic R. Cundari Chief Commercial Officer
David J. Wambeke Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 ARS Filing
Mar 28, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 28, 2025 DEF 14A Other definitive proxy statements
Mar 17, 2025 10-K Annual Report
Mar 17, 2025 8-K Current Report
Mar 6, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Aug 7, 2024 8-K Current Report